KIORA PHARMACEUTICALS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
KIORA PHARMACEUTICALS, INC. (KPRX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of $11.09 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2022-11-09
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-12-31 was -$2.83M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-09-30 was -$4.14M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-06-30 was -$3.33M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-03-31 was -$2.92M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$13.22M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2016 was -$13.34M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2015 was -$8.39M.
- KIORA PHARMACEUTICALS, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2014 was -$1.55M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2022-09-30 | $11.09M 10-Q · filed 2022-11-09 | |||
| 2021-09-30 | $7.59M 10-Q · filed 2022-11-09 | |||
| 2017-12-31 | -$2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | -$6.97M derived: sum of 2 quarters · filed 2018-03-02 | -$10.30M derived: sum of 3 quarters · filed 2018-03-02 | -$13.22M 10-K · filed 2018-03-02 |
| 2017-09-30 | -$4.14M 10-Q · filed 2017-11-14 | -$7.47M derived: sum of 2 quarters · filed 2017-11-14 | -$10.39M 10-Q · filed 2017-11-14 | -$14.09M derived: sum of 4 quarters · filed 2018-03-02 |
| 2017-06-30 | -$3.33M 10-Q · filed 2017-08-04 | -$6.25M 10-Q · filed 2017-08-04 | -$9.95M derived: sum of 3 quarters · filed 2018-03-02 | -$13.32M derived: sum of 4 quarters · filed 2018-03-02 |
| 2017-03-31 | -$2.92M 10-Q · filed 2017-05-05 | -$6.62M derived: sum of 2 quarters · filed 2018-03-02 | -$10.00M derived: sum of 3 quarters · filed 2018-03-02 | -$13.82M derived: sum of 4 quarters · filed 2018-03-02 |
| 2016-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | -$7.08M derived: sum of 2 quarters · filed 2018-03-02 | -$10.90M derived: sum of 3 quarters · filed 2018-03-02 | -$13.34M 10-K · filed 2018-03-02 |
| 2016-09-30 | -$3.38M 10-Q · filed 2017-11-14 | -$7.20M derived: sum of 2 quarters · filed 2017-11-14 | -$9.64M 10-Q · filed 2017-11-14 | -$12.33M derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | -$3.82M 10-Q · filed 2017-08-04 | -$6.27M 10-Q · filed 2017-08-04 | -$8.96M derived: sum of 3 quarters · filed 2017-08-04 | -$10.31M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | -$2.44M 10-Q · filed 2017-05-05 | -$5.13M derived: sum of 2 quarters · filed 2017-05-05 | -$6.49M derived: sum of 3 quarters · filed 2017-05-05 | -$8.03M derived: sum of 4 quarters · filed 2017-05-05 |
| 2015-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$4.05M derived: sum of 2 quarters · filed 2017-02-23 | -$5.59M derived: sum of 3 quarters · filed 2017-02-23 | -$8.39M 10-K · filed 2017-02-23 |
| 2015-09-30 | -$1.36M 10-Q · filed 2016-11-01 | -$2.90M derived: sum of 2 quarters · filed 2016-11-01 | -$5.70M 10-Q · filed 2016-11-01 | -$6.05M derived: sum of 4 quarters · filed 2016-11-01 |
| 2015-06-30 | -$1.54M 10-Q · filed 2016-08-10 | -$4.34M 10-Q · filed 2016-08-10 | -$4.69M derived: sum of 3 quarters · filed 2016-08-10 | -$4.34M derived: sum of 4 quarters · filed 2016-08-10 |
| 2015-03-31 | -$2.80M 10-Q · filed 2016-05-13 | -$3.15M derived: sum of 2 quarters · filed 2016-05-13 | -$2.80M derived: sum of 3 quarters · filed 2016-05-13 | -$3.45M derived: sum of 4 quarters · filed 2016-05-13 |
| 2014-12-31 | -$351.94K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$1.68K derived: sum of 2 quarters · filed 2016-03-30 | -$648.62K derived: sum of 3 quarters · filed 2016-03-30 | -$1.55M 10-K · filed 2016-03-30 |
| 2014-09-30 | $350.26K 10-Q · filed 2015-11-12 | -$296.68K derived: sum of 2 quarters · filed 2015-11-12 | -$1.20M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$646.93K 10-Q · filed 2015-08-12 | -$1.55M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$902.89K 10-Q · filed 2015-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |